{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:19:03Z","timestamp":1790176743887,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002158","name":"Jackson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002158","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.vaccine.2016.05.010","type":"journal-article","created":{"date-parts":[[2016,5,10]],"date-time":"2016-05-10T22:29:52Z","timestamp":1462919392000},"page":"3260-3267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Evaluation of various adjuvant nanoparticulate formulations for meningococcal capsular polysaccharide-based vaccine"],"prefix":"10.1016","volume":"34","author":[{"given":"Rikhav P.","family":"Gala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susu M.","family":"Zughaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"June (9580)","key":"10.1016\/j.vaccine.2016.05.010_bib0325","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet Lond Engl"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2016.05.010_bib0330","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1086\/313754","article-title":"Fulminant meningococcal septicemia: dissociation between plasma thrombopoietin levels and platelet counts","volume":"30","author":"Bjerre","year":"2000","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"May (22)","key":"10.1016\/j.vaccine.2016.05.010_bib0335","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","article-title":"A review of vaccine research and development: meningococcal disease","volume":"24","author":"Girard","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2016.05.010_bib0340","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2016.05.010_bib0345","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1189\/jlb.0610369","article-title":"Neisseria meningitidis capsular polysaccharides induce inflammatory responses via TLR2 and TLR4-MD-2","volume":"89","author":"Zughaier","year":"2011","journal-title":"J Leukoc Biol"},{"issue":"March (11)","key":"10.1016\/j.vaccine.2016.05.010_bib0350","first-page":"1453","article-title":"Dakar discussion group on priorities for research on epidemic meningococcal disease in Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt","volume":"31","author":"Africa","year":"2013","journal-title":"Vaccine"},{"issue":"January (5)","key":"10.1016\/j.vaccine.2016.05.010_bib0355","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.vaccine.2008.11.065","article-title":"Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa","volume":"27","author":"Lee","year":"2009","journal-title":"Vaccine"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2016.05.010_bib0360","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2016.05.010_bib0365","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1186\/s12879-014-0546-8","article-title":"Evolution of meningococcal carriage in serogroups X and Y before introduction of MenAfriVac in the health district of Kaya, Burkina Faso","volume":"14","author":"Ba","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2016.05.010_bib0370","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01974-14","article-title":"Emergence of a new epidemic Neisseria meningitidis serogroup A Clone in the African meningitis belt: high-resolution picture of genomic changes that mediate immune evasion","volume":"5","author":"Lamelas","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2016.05.010_bib0375","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/1471-2334-13-576","article-title":"Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination","volume":"13","author":"Collard","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2016.05.010_bib0380","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","article-title":"Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger","volume":"44","author":"Boisier","year":"2007","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"June (27)","key":"10.1016\/j.vaccine.2016.05.010_bib0385","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.vaccine.2013.04.036","article-title":"Emergence of serogroup X meningococcal disease in Africa: need for a vaccine","volume":"31","author":"Xie","year":"2013","journal-title":"Vaccine"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2016.05.010_bib0390","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/INF.0000000000000438","article-title":"Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents","volume":"33","author":"Baxter","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2016.05.010_bib0395","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/02652048.2012.692402","article-title":"Formulation of meningococcal capsular polysaccharide vaccine-loaded microparticles with robust innate immune recognition","volume":"30","author":"Ubale","year":"2013","journal-title":"J Microencapsul"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2016.05.010_bib0400","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1208\/s12248-014-9635-2","article-title":"Induction of death receptor CD95 and co-stimulatory molecules CD80 and CD86 by meningococcal capsular polysaccharide-loaded vaccine nanoparticles","volume":"16","author":"Ubale","year":"2014","journal-title":"AAPS J"},{"issue":"March (1)","key":"10.1016\/j.vaccine.2016.05.010_bib0405","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/vaccines3010148","article-title":"Choice and design of adjuvants for parenteral and mucosal","volume":"3","author":"Savelkoul","year":"2015","journal-title":"Vaccines"},{"issue":"April (17)","key":"10.1016\/j.vaccine.2016.05.010_bib0410","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"issue":"January","key":"10.1016\/j.vaccine.2016.05.010_bib0415","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2013.10.032","article-title":"Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles","volume":"173","author":"Li","year":"2014","journal-title":"J Controlled Release"},{"issue":"February (13)","key":"10.1016\/j.vaccine.2016.05.010_bib0420","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.vaccine.2004.07.050","article-title":"Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro","volume":"23","author":"Morefield","year":"2005","journal-title":"Vaccine"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2016.05.010_bib0425","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.clpt.6100402","article-title":"MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?","volume":"82","author":"O\u2019Hagan","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2016.05.010_bib0430","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol Cell Biol"},{"issue":"October (5)","key":"10.1016\/j.vaccine.2016.05.010_bib0435","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/14760584.6.5.685","article-title":"Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation","volume":"6","author":"Hem","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"June (26)","key":"10.1016\/j.vaccine.2016.05.010_bib0440","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.vaccine.2008.03.093","article-title":"Safety of MF59 adjuvant","volume":"26","author":"Schultze","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.010_bib0445","unstructured":"The Novartis Institutes for BioMedical Research (NIBR) is a global research organization committed to discovering innovative m - MF59-Adj-fact-sheet.pdf [Internet]. [cited 2015 May 20]. Available from: https:\/\/www.novartisvaccines.com\/downloads\/diseases-products\/MF59-Adj-fact-sheet.pdf"},{"issue":"March (17\u201319)","key":"10.1016\/j.vaccine.2016.05.010_bib0450","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0264-410X(00)00499-0","article-title":"The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine","volume":"19","author":"Podda","year":"2001","journal-title":"Vaccine"},{"issue":"May (22)","key":"10.1016\/j.vaccine.2016.05.010_bib0455","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1016\/j.vaccine.2007.03.029","article-title":"TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A","volume":"25","author":"Zughaier","year":"2007","journal-title":"Vaccine"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2016.05.010_bib0460","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/08830185.2013.773326","article-title":"Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects","volume":"32","author":"Kuroda","year":"2013","journal-title":"Int Rev Immunol"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2016.05.010_bib0465","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","article-title":"Toll-like receptors and their crosstalk with other innate receptors in infection and immunity","volume":"34","author":"Kawai","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2016.05.010_bib0470","unstructured":"UCM131170.pdf [Internet]. [cited 2015 May 21]. Available from: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM131170.pdf"},{"key":"10.1016\/j.vaccine.2016.05.010_bib0475","unstructured":"[Product Monograph Template - Schedule D] - Nimenrix.pdf [Internet]. [cited 2015 Sep 21]. Available from: http:\/\/www.gsk.ca\/english\/docs-pdf\/product-monographs\/Nimenrix.pdf"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2016.05.010_bib0480","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1128\/IAI.70.7.3707-3713.2002","article-title":"Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses","volume":"70","author":"Berry","year":"2002","journal-title":"Infect Immun"},{"issue":"December (8)","key":"10.1016\/j.vaccine.2016.05.010_bib0485","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/02652040802476187","article-title":"Formulation and evaluation of albumin microspheres and its enteric coating using a spray-dryer","volume":"25","author":"Bejugam","year":"2008","journal-title":"J Microencapsul"},{"key":"10.1016\/j.vaccine.2016.05.010_bib0490","series-title":"Novel approaches and strategies for biologics, vaccines and cancer therapies","first-page":"520","author":"Singh","year":"2014"},{"issue":"August (7)","key":"10.1016\/j.vaccine.2016.05.010_bib0495","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/10611860903067301","article-title":"Oral delivery of gastro-resistant microencapsulated typhoid vaccine","volume":"17","author":"Uddin","year":"2009","journal-title":"J Drug Target"},{"issue":"3","key":"10.1016\/j.vaccine.2016.05.010_bib0500","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3109\/02652048.2012.720724","article-title":"Microencapsulation of protein into biodegradable matrix: a smart solution cross-linking technique","volume":"30","author":"Bejugam","year":"2013","journal-title":"J Microencapsul"},{"issue":"4","key":"10.1016\/j.vaccine.2016.05.010_bib0505","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3109\/02652048.2011.651503","article-title":"Spray-dried microparticles: a potential vehicle for oral delivery of vaccines","volume":"29","author":"Chablani","year":"2012","journal-title":"J Microencapsul"},{"issue":"August (38)","key":"10.1016\/j.vaccine.2016.05.010_bib0510","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2012.05.073","article-title":"Formulation and evaluation of oral microparticulate ovarian cancer vaccines","volume":"30","author":"Tawde","year":"2012","journal-title":"Vaccine"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2016.05.010_bib0515","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/jps.23220","article-title":"Immunogenicity and protection of oral influenza vaccines formulated into microparticles","volume":"101","author":"Shastri","year":"2012","journal-title":"J Pharm Sci"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2016.05.010_bib0520","first-page":"2723","article-title":"Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules","volume":"158","author":"Shen","year":"1997","journal-title":"J Immunol Baltim Md 1950"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2016.05.010_bib0525","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/IAI.72.1.371-380.2004","article-title":"Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14\/Toll-like receptor 4 pathway","volume":"72","author":"Zughaier","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.05.010_bib0530","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev-immunol-030409-101159","article-title":"How bacterial carbohydrates influence the adaptive immune system","volume":"28","author":"Avci","year":"2010","journal-title":"Annu Rev Immunol"},{"issue":"May (1)","key":"10.1016\/j.vaccine.2016.05.010_bib0535","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2567.2008.02924.x","article-title":"Type I Streptococcus pneumoniae carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation","volume":"127","author":"Velez","year":"2009","journal-title":"Immunology"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2016.05.010_bib0540","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1462-5822.2005.00591.x","article-title":"Zwitterionic capsular polysaccharides: the new MHCII-dependent antigens","volume":"7","author":"Cobb","year":"2005","journal-title":"Cell Microbiol"},{"issue":"10","key":"10.1016\/j.vaccine.2016.05.010_bib0545","doi-asserted-by":"crossref","first-page":"e23995","DOI":"10.1371\/journal.pone.0023995","article-title":"Penicillin binding proteins as danger signals: meningococcal penicillin binding protein 2 activates dendritic cells through Toll-like receptor 4","volume":"6","author":"Hill","year":"2011","journal-title":"PloS One"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2016.05.010_bib0550","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1517\/14712598.7.10.1551","article-title":"Adjuvants in vaccines and for immunisation: current trends","volume":"7","author":"Chiarella","year":"2007","journal-title":"Expert Opin Biol Ther"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2016.05.010_bib0555","first-page":"881","article-title":"Complement activation by aluminium and zirconium compounds","volume":"37","author":"Ramanathan","year":"1979","journal-title":"Immunology"},{"issue":"July (27)","key":"10.1016\/j.vaccine.2016.05.010_bib0560","doi-asserted-by":"crossref","first-page":"11169","DOI":"10.1073\/pnas.1107941108","article-title":"Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88","volume":"108","author":"Seubert","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"June (29)","key":"10.1016\/j.vaccine.2016.05.010_bib0565","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59 - an innately attractive adjuvant formulation","volume":"30","author":"O\u2019Hagan","year":"2012","journal-title":"Vaccine"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2016.05.010_bib0570","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"December (24)","key":"10.1016\/j.vaccine.2016.05.010_bib0575","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1016\/j.febslet.2010.11.036","article-title":"Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters","volume":"584","author":"Saito","year":"2010","journal-title":"FEBS Lett"},{"issue":"October (5)","key":"10.1016\/j.vaccine.2016.05.010_bib0580","first-page":"575","article-title":"Meningococcal disease: a review on available vaccines and vaccines in development","volume":"98","author":"Br\u00f6ker","year":"2007","journal-title":"Minerva Med"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2016.05.010_bib0585","first-page":"4371","article-title":"Dendritic cell differentiation state and their interaction with NKT cells determine Th1\/Th2 differentiation in the murine model of Leishmania major infection","volume":"180","author":"Wiethe","year":"2008","journal-title":"J Immunol Baltim Md 1950"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2016.05.010_bib0590","first-page":"1325","article-title":"Limited ability of antigen-specific Th1 responses to inhibit Th2 cell development in vivo","volume":"174","author":"Yasumi","year":"2005","journal-title":"J Immunol Baltim Md 1950"},{"issue":"July (6093)","key":"10.1016\/j.vaccine.2016.05.010_bib0595","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1126\/science.1221064","article-title":"New paradigms in type 2 immunity","volume":"337","author":"Pulendran","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.05.010_bib0600","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1038\/ncomms5092","article-title":"Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand","volume":"5","author":"Maddur","year":"2014","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.vaccine.2016.05.010_bib0605","doi-asserted-by":"crossref","first-page":"e114366","DOI":"10.1371\/journal.pone.0114366","article-title":"Novel anti-nicotine vaccine using a trimeric coiled-coil hapten carrier","volume":"9","author":"Miller","year":"2014","journal-title":"PloS One"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2016.05.010_bib0610","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/ACI.0b013e32834cb994","article-title":"Long-term clinical and immunological effects of allergen immunotherapy","volume":"11","author":"Eifan","year":"2011","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2016.05.010_bib0615","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00430-014-0367-9","article-title":"Evaluation of the immunogenicity and protective efficacy of Killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis","volume":"204","author":"Thakur","year":"2015","journal-title":"Med Microbiol Immunol (Berl)"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2016.05.010_bib0620","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00130832-200412000-00012","article-title":"Adjuvants for allergen immunotherapy: experimental results and clinical perspectives","volume":"4","author":"Francis","year":"2004","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2016.05.010_bib0625","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2337\/dc13-1719","article-title":"GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial","volume":"37","author":"Krause","year":"2014","journal-title":"Diabetes Care"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2016.05.010_bib0630","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.nmd.2006.02.004","article-title":"AlOH3-adjuvanted vaccine-induced macrophagic myofasciitis in rats is influenced by the genetic background","volume":"16","author":"Authier","year":"2006","journal-title":"Neuromuscul Disord NMD"},{"issue":"December (11-12)","key":"10.1016\/j.vaccine.2016.05.010_bib0635","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3109\/00365548.2011.608714","article-title":"Explorations of clinical trials and pharmacovigilance databases of MF59\u00ae-adjuvanted influenza vaccines for associated cases of narcolepsy: a six-month update","volume":"43","author":"Crucitti","year":"2011","journal-title":"Scand J Infect Dis"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2016.05.010_bib0640","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0961203311429557","article-title":"Macrophagic myofasciitis: characterization and pathophysiology","volume":"21","author":"Gherardi","year":"2012","journal-title":"Lupus"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16302936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16302936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T04:52:56Z","timestamp":1536727976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16302936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":64,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0264410X16302936"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.05.010","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of various adjuvant nanoparticulate formulations for meningococcal capsular polysaccharide-based vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}